Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Gilson

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Cytokine|May 2, 2016
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSFSam Nightingale, Benedict D Michael, Martin Fisher, et al.
The Journal of Infectious Diseases|January 27, 2012
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?Mark Gompels, David T Dunn, Andrew Phillips, et al.
AIDS and Behavior|October 12, 2018
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual BehaviourMitzy Gafos, Rob Horne, Will Nutland, et al.
AIDS (London, England)|February 22, 2014
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapyMargaret T May, Mark Gompels, Valerie Delpech, et al.
Infectious Diseases and Therapy|April 19, 2023
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE StudySamuel M Brown, Morgan J Katz, Adit A Ginde, et al.
AIDS (London, England)|January 16, 2008
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi, Andrew A Benzie, Andrew N Phillips, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
AIDS (London, England)|December 17, 2013
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppressionJemma L O'Connor, Colette J Smith, Fiona C Lampe, et al.
Antiviral Therapy|September 9, 2011
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber, Anna Maria Geretti, Jane Anderson, et al.
AIDS (London, England)|December 7, 2023
Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIVAmelia E B Moore, James E Burns, Deirdre Sally, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Cytokine|May 2, 2016
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSFSam Nightingale, Benedict D Michael, Martin Fisher, et al.
The Journal of Infectious Diseases|January 27, 2012
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?Mark Gompels, David T Dunn, Andrew Phillips, et al.
AIDS and Behavior|October 12, 2018
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual BehaviourMitzy Gafos, Rob Horne, Will Nutland, et al.
AIDS (London, England)|February 22, 2014
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapyMargaret T May, Mark Gompels, Valerie Delpech, et al.
Infectious Diseases and Therapy|April 19, 2023
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE StudySamuel M Brown, Morgan J Katz, Adit A Ginde, et al.
AIDS (London, England)|January 16, 2008
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi, Andrew A Benzie, Andrew N Phillips, et al.
The Lancet. HIV|July 1, 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Peter J Ruane, Daniel Podzamczer, et al.
AIDS (London, England)|December 17, 2013
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppressionJemma L O'Connor, Colette J Smith, Fiona C Lampe, et al.
Antiviral Therapy|September 9, 2011
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber, Anna Maria Geretti, Jane Anderson, et al.
AIDS (London, England)|December 7, 2023
Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIVAmelia E B Moore, James E Burns, Deirdre Sally, et al.
Pageof 15